A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie
AbbVie
Eli Lilly and Company
Hoffmann-La Roche
Amgen
Hoffmann-La Roche
EMD Serono
Norwegian University of Science and Technology
AbbVie
Qilu Pharmaceutical Co., Ltd.
Abramson Cancer Center at Penn Medicine
Gustave Roussy, Cancer Campus, Grand Paris
University of Sydney
Spanish Lung Cancer Group
Kalbe International Pte. Ltd
Helsinn Healthcare SA
Helsinn Healthcare SA
Sumitomo Pharma America, Inc.
Amgen
Centus Biotherapeutics Limited
AbbVie
University of Turin, Italy
Clovis Oncology, Inc.
Shanghai University of Traditional Chinese Medicine
Shanghai University of Traditional Chinese Medicine
AbbVie
Ospedale Santa Croce-Carle Cuneo
Daiichi Sankyo
Shanghai Gebaide Biotechnology Co., Ltd.
Amgen
Mario Negri Institute for Pharmacological Research
Bayer
GlaxoSmithKline
INSYS Therapeutics Inc
Ontario Clinical Oncology Group (OCOG)
AstraZeneca
Hellenic Oncology Research Group
Ontario Clinical Oncology Group (OCOG)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hellenic Oncology Research Group
Hellenic Oncology Research Group
Amgen
Pharmacyclics LLC.